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Peripheral arterial disease (PAD) is a disorder character-
ized by narrowing or occlusion of the arteries that result 
in a lack of adequate arterial blood to the limbs. Approxi-
mately 120 to 140 million people suffer from diabetes 
mellitus (DM) worldwide and patients with diabetes more 
commonly develop symptomatic PAD.1) The Framingham 
Study showed that the presence of diabetes increased the 
Background: This study evaluated the effects of Beraprost sodium (Berasil) on subjective leg symptoms in patients with periph-
eral arterial disease caused by diabetes mellitus. 
Methods: Ninety-four diabetic patients with peripheral arterial disease were treated with Beraprost in a fixed-dose, prospective, 
multicenter, cohort study. Beraprost (40 µg) was administered orally 3 times daily (120 µg/day) for 12 weeks. We developed a new 
disease-specific symptom questionnaire, which evaluated the effect of peripheral arterial disease on leg discomfort in daily life 
and assessed therapeutic responses to treatment. Patients were asked for their subjective assessment of symptoms on a written 
questionnaire before treatment and after 12 weeks of therapy. 
Results: There was significant improvement in all estimated subjective symptoms (burning, coldness, edema, exertional pain, 
stabbing, and paresthesias) in the lower extremities at 12 weeks (p  < 0.001). There were 18 patients with neuropathy in whom sig-
nificant improvement was noted for 6 subjective symptoms at 12 weeks (p  < 0.05). Adverse events considered to be drug-related 
were observed in 4 patients (4.3%), all of which were mild and resolved with discontinuation of the medication.
Conclusions: Beraprost is effective as a treatment for improving various subjective symptoms in the lower extremities, such as 
burning, coldness, edema, exertional pain, stabbing, and paresthesias, in diabetic patients with peripheral arterial disease. 
Keywords: Peripheral arterial disease, Intermittent claudication, Diabetes mellitus, Beraprost sodium, Prostaglandin I2
risk of developing PAD by 3.5- and 8.6-fold among men 
and women, respectively.2) PAD in DM is more severe in 
extent and progresses more rapidly than in non-diabetic 
patients.3)
The goals in treatment of the patients with PAD 
are the improvement in symptoms and prevention of car-
diovascular events. Many agents, including antiplatelet 
drugs and vasodilators, have been tried for pain relief, 
although their effectiveness remains the subject of debate. 
Prostaglandin I2 (PGI2), a naturally occurring prostanoid, 
promotes vasodilatation,4,5) inhibits platelet aggregation,4,5) 
and suppresses smooth muscle proliferation.6) Beraprost 
sodium (Berasil, Astellas Pharma Korea, Seoul, Korea) 
is an orally active PGI2 analogue with antiplatelet and 
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vasodilating properties.7,8) The Beraprost et Claudication 
Intermittent study (BERCI-2), a double-blind, random-
ized, and multicenter controlled trial in France and Italy, 
demonstrated that both maximum walking distance and 
pain-free walking distance were increased significantly in 
patients receiving Beraprost.9) However, only a few patients 
with non-insulin dependent DM were included and pa-
tients with insulin dependent DM were excluded in their 
study. Most of the previous studies regarding the effects of 
Beraprost on PAD have not addressed diabetic patients9,10) 
and only a few studies have been performed in regard to 
the treatment of Beraprost in diabetic patients with PAD.11)
Intermittent claudication has been considered the 
most characteristic manifestation of PAD.12) The best way 
of evaluating ambulatory function and assessing the sever-
ity of intermittent claudication in patients with PAD is by 
measuring maximal walking distance and time recorded 
during a treadmill exercise test.13) However, in community-
based epidemiologic studies, many people with PAD have 
symptoms other than classic intermittent claudication.14-16) 
Therefore, a treadmill exercise test cannot always accu-
rately reflect the symptoms patients experienced in their 
daily life. Questionnaires are frequently used as a tool to 
assess pain syndromes. Current pain questionnaires, such 
as the McGill Pain Questionnaire17) and the Neuropathic 
Pain Scale,18) are not specific enough for the assessment 
of the different symptoms of diabetic patients with PAD. 
To our knowledge, there have been no studies that have 
evaluated the intensity and quality of subjective symptoms 
or have assessed the ability of Beraprost to improve these 
symptoms in diabetic patients with PAD. We developed a 
new disease-specific symptom questionnaire, which evalu-
ated the effects of PAD on leg discomfort in daily life in 
order to assess therapeutic responses to Beraprost. The 
present study aimed to evaluate the effects of Beraprost for 
improving subjective leg symptoms using the newly de-
vised, disease-specific symptom questionnaire in patients 
with peripheral arterial diseases and diabetes.
METHODS
The current investigation was a prospective, multicenter, 
cohort study conducted at third referral hospitals in South 
Korea, between December 2009 and October 2010. Pa-
tients who met the following criteria were included in this 
study: 1) between 18 and 90 years of age; 2) an established 
diagnosis of DM; 3) lower limb discomfort for longer than 
six months; 4) a diagnosis of PAD established by the ab-
sence of one or more foot pulses of the involved foot or an 
ankle brachial pressure index (ABI) less than 0.9. Patients 
were excluded from the study if they had critical limb isch-
emia, defined as the presence of rest pain requiring anal-
gesics for a duration of more than 2 weeks, the presence 
of non-healing ischemic ulcer, or gangrene; a stroke or 
myocardial infraction within the last 3 months; a tendency 
towards hemorrhage; severe liver or kidney disease; hav-
ing undergone endovascular intervention of the coronary 
artery or a peripheral artery; or having undergone opera-
tive revascularization within the last 3 months. With these 
strict inclusion and exclusion criteria, 100 diabetic patients 
with PAD were enrolled in this study, 6 of whom were ex-
cluded because they chose to discontinue the medication. 
All patients who were eligible for the study agreed to par-
ticipate and signed a written informed consent. This study 
was performed according to the Declaration of Helsinki 
and was approved by the respective local Institutional 
Review Boards from the institutions participating in the 
study.
Patients were administered oral Beraprost (40 µg) 3 
times daily (120 µg/day) for 12 weeks. Use of other drugs 
with significant effects on peripheral vessels, hemosta-
sis, or platelet function during the study was prohibited. 
Among these included pentoxifylline, heparin, warfarin, 
aspirin, persantine, ticlopidine, and prostaglandin E1 
analogs. All other medical care regimens were continued 
throughout the course of the study in all the patients.
The following safety assessments were made before 
treatment, as well as 6 weeks and 12 weeks thereafter, or 
at drug discontinuation: serum chemistry, hematology, 
electrocardiogram, vital signs, concomitant medication 
changes, and adverse events.
Construction of the Questionnaire
First, a list of descriptors was chosen on the basis of our 
experience and analysis of the literature. Following dis-
cussions and approval of content validity by a panel of 4 
Korean diabetic foot experts, we included 8 descriptors 
(burning, coldness, edema, exertional pain, throbbing, 
shooting, stabbing, and paresthesias) in the initial version 
of the questionnaire. A pilot study was performed in all 
patients who participated in this study at their first visit in 
order to verify the face validity of the questionnaire. The 
patients were asked to complete the questionnaire and to 
rate each descriptor for clarity in wording, understanding, 
and relevance to their current symptoms. After the pilot 
study, the “throbbing” descriptor was excluded because it 
was considered irrelevant by a majority of patients. In ad-
dition, the “shooting” descriptor was excluded because of 
very low prevalence (< 30% of the patients reported the 
symptom) as compared to the other descriptors. Thus, the 
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final version of the disease-specific symptom question-
naire included 6 descriptors: burning, coldness, edema, 
exertional pain, stabbing, and paresthesias. Each subjec-
tive symptom was ranked from 0 to 4, according to the 
severity of the symptoms felt by the patient; 0 reflected 
asymptomatic status and 4 reflected the greatest severity. 
Patients were asked for their subjective assessment of their 
symptoms in the written questionnaire before treatment 
and at 12 weeks. In addition to the assessment of subjec-
tive symptoms, patients were evaluated serially for new 
complaints, changes in symptoms, and functional status. 
Statistical Analysis
Statistical analyses were consequently performed with the 
SPSS ver. 18.0 (IBM Co., Armonk, NY, USA). Differences 
between pretreatment and the last follow-up were ana-
lyzed by the Wilcoxon matched-paired signed-ranks test. 
A value of p < 0.05 was considered statistically significant. 
RESULTS
Among 94 patients included in the evaluation, 90 patients 
completed the study. Four patients failed to qualify for the 
study because of adverse reactions to Beraprost, the study 
medication. Table 1 shows the patients’ demographics. The 
mean age was 63.5 years (range, 30 to 83 years) and the 
mean duration of DM was 9.3 years (range, 1 to 30 years). 
Table 1. Demographics of the Study Population
Characteristic Value
Sex (male:female) 44:46
Age (yr), mean ± SD 63.53 ± 11.24
Body mass index (kg/m2), mean ± SD 23.14 ± 3.19
Duration of DM (yr), mean ± SD 9.31 ± 7.77
Complications of DM 
Diabetic retinopathy 8
Diabetic nephropathy 11
Diabetic neuropathy 18
Comorbidities*
Present 59
Absent 31
Smoking 10
DM: diabetes mellitus.
*These include hypertension, hyperlipidemia, and previous myocardial 
infarction.
Table 2. Changes in Symptom Score after Beraprost Sodium 
Treatment in Patients
Symptom Baseline Study end p-value
Burning < 0.001
0 34 (37.8) 43 (47.8)
1 18 (20.0) 24 (26.7)
2 18 (20.0) 19 (21.1)
3 18 (20.0) 2 (2.2)
4 2 (2.2) 2 (2.2)
Coldness < 0.001
0 9 (10.0) 16 (17.8)
1 9 (10.0) 21 (23.3)
2 23 (25.6) 44 (48.9)
3 42 (46.7) 8 (8.9)
4 7 (7.8) 1 (1.1)
Edema < 0.001
0 16 (17.8) 29 (32.2)
1 34 (37.8) 36 (40.0)
2 25 (27.8) 20 (22.2)
3 2 (2.2) 0 (0.0)
4 13 (14.4) 5 (5.6)
Exertional pain < 0.001
0 7 (7.8) 21 (23.3)
1 16 (17.8) 26 (28.9)
2 23 (35.6) 35 (38.9)
3 36 (40.0) 8 (8.9)
4 8 (8.9) 0 (0.0)
Stabbing < 0.001
0 28 (31.1) 37 (41.1)
1 13 (14.4) 33 (36.7)
2 35 (38.9) 16 (17.8)
3 14 (15.6) 4 (4.4)
4 0 (0.0) 0 (0)
Paresthesia < 0.001
0 23 (25.6) 26 (28.9)
1 7 (7.8) 21 (23.3)
2 23 (25.6) 27 (30.0)
3 32 (35.6) 16 (17.8)
4 5 (5.6) 0 (0.0)
Values are presented as number (%).
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Diabetic retinopathy, nephropathy, and neuropathy were 
present in 8 patients (8.9%), 11 patients (12.2%), 18 pa-
tients (20.0%), respectively, some of whom had more than 
one complication. Comorbidities, including hyperten-
sion, hyperlipidemia, and previous myocardial infarction 
were noted in 57 patients. Ten patients were either current 
smokers or had a history of smoking within the past 2 
years. No specific counseling on diet, smoking cessation or 
exercise was offered during the study period. These factors 
were not specifically controlled.
Table 2 lists the scores for each symptom at baseline 
and after Beraprost treatment. The most commonly re-
ported symptom was exertional pain (83 patients, 92.2%). 
Of these patients, 69.9% reported improvement in their 
symptoms. Of 81 patients with coldness, 59 patients 
(72.8%) showed improvement in their symptoms, 21 pa-
tients (25.9%) remained the same, and one patient (1.2%) 
worsened. Coldness was the most improved among the 
subjective symptoms with taking the medication. Seventy-
four patients had edema, and 39 patients (52.7%) showed 
improvement in this symptom. Stabbing, burning, and 
paresthesias were observed in 61, 56, and 67 patients, re-
spectively, and 65.6%, 64.3%, and 55.2% of them showed 
improvement in the respective symptoms. Significant im-
provement in all estimated subjective symptoms (coldness, 
edema, exertional pain, stabbing, burning, and paresthe-
sias) in the lower extremities was reported at 12 weeks (p 
< 0.001).
There were 18 patients with neuropathy that was de-
termined by an absent protective threshold using a 5.07 (10 
g) Semmes-Weinstein monofilament. With the numbers 
available, these patients that had accompanying neuropa-
thy showed significant improvement in all 6 subjective 
symptoms at 12 weeks (p < 0.05) (Table 3).
There were no reports of critical cardiovascular 
events, including myocardial infarction, transient ischemic 
attack or ischemic gangrene, during the treatment period 
with Beraprost. Adverse reactions considered to be caus-
ally related to Beraprost occurred in 4 of the 94 patients 
(4.3%), and all of these patients discontinued treatment 
prematurely. Headache was the most common complaint, 
occurring in 2 patients (2.1%). Insomnia (one patient) 
and dyspepsia (one patient) were reported as well. All ad-
verse events were mild and resolved after discontinuing 
the medication. No significant changes were noted in the 
safety assessment thereof. 
DISCUSSION
Treatment of PAD can be considered to take part in 3 
stages: lifestyle and risk factor modification, pharmaco-
therapies, and revascularization. Treatment of the patient’s 
lower extremity symptoms should be chosen on the ba-
sis of the severity of the symptoms. Pharmacotherapy 
includes vasodilating agents, calcium channel blockers, 
anticoagulants, antiplatelets, and prostaglandin analogs. A 
revascularization procedure, including surgical or endo-
vascular intervention, is usually reserved for patients with 
disabling claudication that affects their quality of life, after 
medical therapy has failed to improve symptoms and criti-
cal limb ischemia symptoms.
Various medications have been investigated in pa-
tients with PAD. Currently, 2 agents are available in the 
United States for the symptomatic treatment of PAD: 
pentoxifylline and cilostazol. Both drugs have shown to 
increase pain-free walking time and total distance walked, 
although the data on pentoxifylline is conflicting.19,20) In 
comparison with the placebo, cilostazol improved the 
Table 3. Improvement Rating for Subjective Symptoms in Patients 
with Diabetic Neuropathy*
Symptom Improvement No. (%)
Burning Improved 10 (55.6)
Unchanged 7 (38.9)
Worsened 1 (5.6)
Coldness Improved 14 (77.8)
Unchanged 4 (22.2)
Worsened 0 (0)
Edema Improved 12 (66.7)
Unchanged 6 (33.3)
Worsened 0 (0)
Exertional pain Improved 10 (55.6)
Unchanged 8 (44.4)
Worsened 0 (0)
Stabbing Improved 15 (83.3)
Unchanged 3 (16.7)
Worsened 0 (0)
Paresthesia Improved 10 (55.6)
Unchanged 7 (38.9)
Worsened 1 (5.6)
*There was a significant improvement in all estimated subjective symptoms (p 
< 0.05).
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distance that patients with intermittent claudication were 
able to walk during standardized treadmill testing.21,22) 
However, its use is contraindicated in patients with heart 
failure, and a sizable minority discontinues treatment due 
to gastrointestinal upset or palpitations.
Prostaglandins have also shown clinical benefit in 
reducing the symptoms of intermittent claudication and 
significant increase in walking distance.23,24) PGI2 which 
is synthesized in vascular endothelial and smooth muscle 
cells, shows antiplatelet action and vasodilating action.4,5) 
Beraprost sodium is a stable, orally active PGI2 analogue, 
launched in Japan in 1992, and is currently used in several 
countries to treat ischemic symptoms in chronic arterial 
occlusion. Beraprost has favorable effects on maximal 
treadmill walking distance and quality of life, while reduc-
ing the incidence of critical cardiovascular events in pa-
tients with intermittent claudication at 6 months.9) How-
ever, another trial of Beraprost that involved 897 patients 
in the United States showed no significant improvement in 
maximal walking distance.10) Although the two trials were 
well designed, only a few patients with DM were included 
in these studies. For that reason, it is necessary to test the 
efficacy of Beraprost treatment in patients with DM spe-
cifically.
PAD treatment is primarily directed at palliating 
symptoms and improving patients’ ambulatory func-
tion. Intermittent claudication has been considered the 
most characteristic manifestation of PAD.12) However, in 
community-based epidemiologic studies, many people 
with PAD have symptoms other than classic intermittent 
claudication.14-16) Significant improvement of pain-free 
walking distance or maximum walking distance has been 
demonstrated. However, if the patients’ subjective symp-
toms assessment is not changed, there is no reason to con-
sider the effect to be beneficial. Thus, we developed a new 
disease-specific symptom questionnaire, which evaluated 
the effects of PAD on leg discomfort in daily life, to assess 
therapeutic responses.
In this study, 6 subjective symptoms were evaluated 
as parameters of the drug effect. Oral administration of 
Beraprost over a period of 12 weeks resulted in significant 
improvement in all measures of subjective symptoms in 
diabetic patients with PAD (p < 0.001). This suggests that 
treatment with Beraprost can improve a patient’s quality 
of life. The most commonly reported symptom was exer-
tional pain (83 patients, 92.2%). Of these patients, 69.9% 
reported improvement in their symptoms. Coldness was 
the next commonly reported subjective symptom, occur-
ring in 90.0% of the enrolled patients, and 72.8% of these 
patients reported improvement in this symptom. Coldness 
was the most improved among the subjective symptoms. 
Neuropathies developing in patients with diabetes 
are known to be heterogeneous in respect to their symp-
toms, pathologic alterations, and pattern of neurologic 
involvement. Chronic neuropathic pain is present in 13% 
to 26% of diabetic patients.25-28) The symptom in diabetic 
painful neuropathy was most often described by the pa-
tients as “burning/hot,” “electric,” sharp,” “achy,” and “tin-
gling”.29) These symptoms are similar to those observed in 
PAD patients. Therefore, when PAD patients accompanied 
with neuropathy are treated with Beraprost, it is difficult 
to predict the outcome. In this study, we observed im-
provement in all of the 6 symptom parameters in patients 
accompanied with neuropathy. Therefore, if PAD is preva-
lent in patients suspected to have diabetic neuropathy, we 
may expect improvement in some symptoms by treating 
PAD.
One study of Beraprost demonstrated that Beraprost 
increased blood flow significantly to the skin of the feet 
in patients with type 2 diabetes.30) Consistent with an in-
crease in ABI, significant improvement in coldness of the 
limb, numbness, and paralysis was observed in diabetic 
patients with PAD after treatment with Beraprost.11) In this 
study, a 12-week treatment with Beraprost significantly 
improved edema (39 of 74 patients, 52.7%) and coldness 
(59 of 83 patients, 72.8%). All of the above suggests that, in 
treatment of diabetic circulatory disorders, Beraprost di-
lates peripheral vessels and increase blood flow to the skin, 
resulting in the improvement of various symptoms.
In the current study, adverse events considered by 
the investigators to be drug-related were observed in 4 
patients (4.3%), including headache (2 patients, 2.1%), 
insomnia (one patient, 1.1%), and dyspepsia (one patient, 
1.1%). All adverse events were mild and resolved with dis-
continuation of the medication. The incidence of adverse 
events in our study was relatively low compared to that in 
previous studies.9-11) This is probably because the period of 
medication was relatively short in our study. 
The limitations of this study include the uncon-
trolled and nonrandomized design, as well as the relatively 
small sample size. In addition, the lack of placebo control 
limits the statistical power of the data. Also, there was a 
limited ability to perform analyses of a subgroup with neu-
ropathy because sample size could be decreased further. 
In the present study, various antipyretic analgesics, tricy-
clic antidepressants, the anticonvulsants gabapentin and 
pregabalin, as well as serotonin and norepinephrine reup-
take inhibitors were used concomitantly with Beraprost. 
Therefore, to verify the contributory effect of Beraprost 
treatment, separate analyses should have been done before 
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and after Beraprost treatment for groups using and not us-
ing each concomitant drug. This study was relatively short 
in duration. However, there was an effort to minimize the 
effects of other variables. No changes in activity or risk 
factor modification were recommended during the trial. 
By minimizing the biases coming from these factors, these 
similarities lent statistical power to our results. Finally, 
objective findings such as ABI and transcutaneous oxy-
gen saturation were not measured to assess the efficacy of 
Beraprost. Instead, this study focused on the effect of Bera-
prost on subjective leg symptoms in diabetic patients with 
PAD. In future prospective randomized studies, evaluation 
of ABI or transcutaneous oxygen saturation are required 
to determine whether objective findings indeed improve.
Diabetic patients with PAD may have various 
symptoms that are generally reproducible during daily 
activities, resulting in a negative impact on quality of life. 
Beraprost is an agent with pharmacological actions unlike 
other drugs in respect to the treatment of PAD. This trial 
showed statistically significant improvement of subjective 
symptoms in diabetic patients with PAD after 12 weeks of 
therapy with Beraprost, even without specific risk-factor 
modification and a directed exercise program. Beraprost 
may present a new option for the treatment of various 
symptoms in diabetic patients with PAD. Further studies 
are needed with a larger sample size and a placebo control 
to confirm our results.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
REFERENCES
1. American Diabetes Association. Peripheral arterial disease 
in people with diabetes. Diabetes Care. 2003;26(12):3333-
41.
2. Kannel WB, McGee DL. Update on some epidemiologic 
features of intermittent claudication: the Framingham Study. 
J Am Geriatr Soc. 1985;33(1):13-8.
3. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral 
arterial disease in diabetic and nondiabetic patients: a 
comparison of severity and outcome. Diabetes Care. 2001; 
24(8):1433-7.
4. Vane JR, Botting RM. Pharmacodynamic profile of prosta-
cyclin. Am J Cardiol. 1995;75(3):3A-10A.
5. Friedman R, Mears JG, Barst RJ. Continuous infusion of 
prostacyclin normalizes plasma markers of endothelial cell 
injury and platelet aggregation in primary pulmonary hy-
pertension. Circulation. 1997;96(9):2782-4.
6. Willis AL, Smith DL, Vigo C, Kluge AF. Effects of prosta-
cyclin and orally active stable mimetic agent RS-93427-
007 on basic mechanisms of atherogenesis. Lancet. 1986; 
2(8508):682-3.
7. Demolis JL, Robert A, Mouren M, Funck-Brentano C, Jail-
lon P. Pharmacokinetics and platelet antiaggregating effects 
of beraprost, an oral stable prostacyclin analogue, in healthy 
volunteers. J Cardiovasc Pharmacol. 1993;22(5):711-6.
8. Nony P, Ffrench P, Girard P, et al. Platelet-aggregation inhi-
bition and hemodynamic effects of beraprost sodium, a new 
oral prostacyclin derivative: a study in healthy male subjects. 
Can J Physiol Pharmacol. 1996;74(8):887-93.
9. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. 
Oral Beraprost sodium, a prostaglandin I(2) analogue, 
for intermittent claudication: a double-blind, random-
ized, multicenter controlled trial. Beraprost et Claudica-
tion Intermittente (BERCI) Research Group. Circulation. 
2000;102(4):426-31.
10. Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch 
AT. Treatment of intermittent claudication with beraprost 
sodium, an orally active prostaglandin I2 analogue: a dou-
ble-blinded, randomized, controlled trial. J Am Coll Car-
diol. 2003;41(10):1679-86.
11. Toyota T, Oikawa S; Beraprost Sodium Study Group. Effects 
of beraprost sodium (Dorner) in patients with diabetes mel-
litus complicated by chronic arterial obstruction. Angiology. 
2002;53(1):7-13.
12. Rose GA. The diagnosis of ischaemic heart pain and in-
termittent claudication in field surveys. Bull World Health 
Organ. 1962;27(6):645-58.
13. Taylor LM, Porter JM. Proposed design for a double blinded 
trial to evaluate medications for treatment of intermittent 
claudication. J Vasc Surg. 1992;15(5):882-4.
14. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm 
index as a marker of atherosclerosis in the Cardiovascular 
Health Study. Cardiovascular Heart Study (CHS) Collabora-
tive Research Group. Circulation. 1993;88(3):837-45.
15. Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, 
Gabriel S. The sensitivity, specificity, and predictive value of 
traditional clinical evaluation of peripheral arterial disease: 
results from noninvasive testing in a defined population. 
151
Yoon et al. Effects of Beraprost Sodium in Diabetics with Peripheral Arterial Diseases
Clinics in Orthopedic Surgery • Vol. 5, No. 2, 2013 • www.ecios.org
Circulation. 1985;71(3):516-22.
16. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. 
Decreased ankle/arm blood pressure index and mortality in 
elderly women. JAMA. 1993;270(4):465-9.
17. Melzack R. The McGill Pain Questionnaire: major proper-
ties and scoring methods. Pain. 1975;1(3):277-99.
18. Krause SJ, Backonja MM. Development of a neuropathic 
pain questionnaire. Clin J Pain. 2003;19(5):306-14.
19. Marso SP, Hiatt WR. Peripheral arterial disease in patients 
with diabetes. J Am Coll Cardiol. 2006;47(5):921-9.
20. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of 
cilostazol and pentoxifylline for treating intermittent claudi-
cation. Am J Med. 2000;109(7):523-30.
21. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. 
Cilostazol has beneficial effects in treatment of intermittent 
claudication: results from a multicenter, randomized, pro-
spective, double-blind trial. Circulation. 1998;98(7):678-86.
22. Beebe HG, Dawson DL, Cutler BS, et al. A new pharma-
cological treatment for intermittent claudication: results of 
a randomized, multicenter trial. Arch Intern Med. 1999; 
159(17):2041-50.
23. Belch JJ, Bell PR, Creissen D, et al. Randomized, double-
blind, placebo-controlled study evaluating the efficacy and 
safety of AS-013, a prostaglandin E1 prodrug, in patients 
with intermittent claudication. Circulation. 1997;95(9):2298-
302.
24. Muller-Buhl U, Diehm C, Krais T, Zimmermann R, Morl H, 
Eckstein HH. Clinical effects of intravenous iloprost in pa-
tients with intermittent claudication. Eur J Clin Pharmacol. 
1987;33(2):127-31.
25. Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The 
natural history of chronic painful peripheral neuropathy in 
a community diabetes population. Diabet Med. 2006;23(9): 
1021-4.
26. Davies M, Brophy S, Williams R, Taylor A. The prevalence, 
severity, and impact of painful diabetic peripheral neuropa-
thy in type 2 diabetes. Diabetes Care. 2006;29(7):1518-22.
27. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; 
KORA Study Group. Prevalence of polyneuropathy in pre-
diabetes and diabetes is associated with abdominal obesity 
and macroangiopathy: the MONICA/KORA Augsburg Sur-
veys S2 and S3. Diabetes Care. 2008;31(3):464-9.
28. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; 
KORA Study Group. Neuropathic pain in diabetes, predia-
betes and normal glucose tolerance: the MONICA/KORA 
Augsburg Surveys S2 and S3. Pain Med. 2009;10(2):393-400.
29. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneu-
ropathy: epidemiology, pain description, and quality of life. 
Diabetes Res Clin Pract. 2000;47(2):123-8.
30. Aso Y, Tayama K, Takanashi K, Inukai T, Takemura Y. 
Changes in skin blood flow in type 2 diabetes induced by 
prostacyclin: association with ankle brachial index and plas-
ma thrombomodulin levels. Metabolism. 2001;50(5):568-72.
